Virus Destroying Or Inhibiting Patents (Class 514/3.7)
  • Patent number: 10781235
    Abstract: Water dispersible, multivalent ligand-lipid constructs that spontaneously and stably incorporate into membranes are disclosed.
    Type: Grant
    Filed: October 28, 2019
    Date of Patent: September 22, 2020
    Inventors: Nicolai Vladimirovich Bovin, Stephen Micheal Henry, Elena Korchagina, Alexander Borisovich Tuzikov, Ludmila Baidakova Pushchino, Rodionov
  • Patent number: 10702572
    Abstract: Provided herein are methods of suppressing viral nucleic acid, e.g. double-stranded (ds) DNA, genome release from or packaging of viruses having their nucleic acid genome packaged under stress in their capsid, and compositions useful for that purpose. The methods alter the ionic environment of the nucleic acid within the capsid and thereby prevent release of, and/or interfere with packaging of the viral genome.
    Type: Grant
    Filed: January 30, 2017
    Date of Patent: July 7, 2020
    Assignee: Carnegie Mellon University
    Inventor: Alex Evilevitch
  • Patent number: 10457706
    Abstract: Water dispersible, multivalent ligand-lipid constructs that spontaneously and stably incorporate into membranes are disclosed.
    Type: Grant
    Filed: November 23, 2015
    Date of Patent: October 29, 2019
    Inventors: Stephen Micheal Henry, Elena Korchagina, Igor Leonidovich Rodionov, Alexander Borisovich Tuzikov
  • Patent number: 10434143
    Abstract: Claimed and disclosed is a new use for a previously approved drug: erythropoietin. The present invention teaches using Erythropoetin to treat anemia caused by the combined treatment of Ribavirin and alpha-interferon. Erythropoetin has previously been approved for the treatment of anemia caused by cancer chemotherapy, renal failure and HIV. It has not been used for anemia caused by ribavirin. Ribavirin is part of a two-drug regimen now used to treat hepatitis C along with alpha interferon. The principal side effect of ribavirin is a hemolytic anemia. In the past, management of that anemia was done by dose reduction of the ribavirin, sometimes resulting in reversal of part of the anemia. It has become particularly important in light of new data, to maximize the dose of ribavirin given to persons undergoing treatment for hepatitis C to ensure a successful eradication of hepatitis C.
    Type: Grant
    Filed: December 27, 2012
    Date of Patent: October 8, 2019
    Inventor: Douglas T. Dieterich
  • Patent number: 9839666
    Abstract: A peptide (SEQ ID NO:5), the use of the peptide for the inhibition of the activity of influenza virus and a pharmaceutical composition containing the peptide are described.
    Type: Grant
    Filed: July 14, 2016
    Date of Patent: December 12, 2017
    Assignee: Wells Resources Limited
    Inventor: Chenlung Lin
  • Patent number: 9694086
    Abstract: The present invention provides compounds, pharmaceutically acceptable compositions thereof, and methods of using the same.
    Type: Grant
    Filed: September 15, 2015
    Date of Patent: July 4, 2017
    Assignee: Celgene CAR LLC
    Inventors: Russell C. Petter, Juswinder Singh, Arthur F. Kluge, Deqiang Niu, Lixin Qiao, Shomir Ghosh
  • Patent number: 9644005
    Abstract: A novel Tistrella mobilis strain having Accession Deposit Number NRRL B-50531 is provided. A method of producing a didemnin precursor, didemnin or didemnin derivative by using the Tistrella mobilis strain, and the therapeutic composition comprising at least one didemnin or didemnin derivative produced from the strain or modified strain thereof are also provided.
    Type: Grant
    Filed: September 21, 2012
    Date of Patent: May 9, 2017
    Assignee: King Abdullah University of Science and Technology
    Inventors: Pei-Yuan Qian, Ying Sharon Xu, Pok-Yui Lai
  • Patent number: 9644002
    Abstract: The present invention includes a novel class of allosteric modulators that target a protein having a juxtamembrane segment. In another embodiment, the allosteric modulator is a peptide mimetic that is capable of interacting with an ?-helix or a coiled coil domain of a protein. In one embodiment, the peptide mimetic binds to at least an ?-helix or a coiled coil domain of EGFR and modulates its activity.
    Type: Grant
    Filed: July 25, 2014
    Date of Patent: May 9, 2017
    Assignee: Yale University
    Inventor: Alanna Schepartz
  • Patent number: 9534029
    Abstract: The present invention relates generally to a method of purifying proteins. More specifically, the present inventions relates to a method of purifying haptoglobin and hemopexin from the same starting material, and uses thereof.
    Type: Grant
    Filed: March 14, 2013
    Date of Patent: January 3, 2017
    Assignee: CSL Behring AG
    Inventor: Nathan Brinkman
  • Patent number: 9388217
    Abstract: Polypeptides that recognize and are strong binders to Influenza A hemagglutinin and can be used, for example, to treat and/or limit development of an influenza infection are disclosed. Isolated nucleic acids encoding the polypeptides of the invention, recombinant expression vectors comprising the nucleic acids encoding the polypeptides of the invention operatively linked to a suitable control sequence, and recombinant host cells comprising the recombinant expression vectors of the invention are disclosed. Antibodies that selectively bind to the polypeptides of the invention, and pharmaceutical compositions comprising one or more polypeptides according to the invention and a pharmaceutically acceptable carrier are disclosed.
    Type: Grant
    Filed: March 12, 2013
    Date of Patent: July 12, 2016
    Assignee: University of Washington through its Center for Commercialization
    Inventors: David Baker, Timothy A. Whitehead, Sarel Fleishman
  • Patent number: 9044480
    Abstract: The present invention features methods of using Compound I to suppress HCV mutants, treat treatment-experienced HCV patients, and treat HCV patients having non-CC IL28B rs12979860 genotype.
    Type: Grant
    Filed: March 5, 2012
    Date of Patent: June 2, 2015
    Assignee: AbbVie Inc.
    Inventors: Tami Pilot-Matias, Isabelle A. Gaultier, Rakesh L. Tripathi, Christine A. Collins, Daniel E. Cohen, Barry M. Bernstein
  • Publication number: 20150147283
    Abstract: The present invention provides methods for limiting development of skin wounds, and also for treatment of one or more of erythemas, blisters, rashes, pruritis, contact dermatitis, psoriasis, eczema, acne, and athlete's foot.
    Type: Application
    Filed: March 14, 2013
    Publication date: May 28, 2015
    Inventors: Kathleen E. Rodgers, Gere S. diZerega
  • Patent number: 9040479
    Abstract: The present invention is directed to compounds, compositions and methods for treating or preventing HCV viral infections in human patients or other animal hosts.
    Type: Grant
    Filed: January 11, 2013
    Date of Patent: May 26, 2015
    Assignee: Cocrystal Pharma, Inc.
    Inventor: Steven J. Coats
  • Publication number: 20150141324
    Abstract: It is provided furin inhibitors and their uses for treating pathogen infection. Particularly, it is provided a method or use for the treatment of a pathogen infection, in a subject, comprising administering to the subject a therapeutically effective amount of the furin inhibitors or the composition disclosed, thereby preventing or treating pathogen infection, in the subject.
    Type: Application
    Filed: August 31, 2012
    Publication date: May 21, 2015
    Applicant: SOCPRA SCIENCES SANTE ET HUMAINES S.E.C.
    Inventors: Robert Day, Witold A. Neugebauer, Yves Dory
  • Publication number: 20150139999
    Abstract: Described are compositions and methods useful for modulating the immune system of a subject. Also included are diagnostic methods for monitoring an immunologic condition. In particular the invention relates to antagonists of interferon proteins and associated methods of use as well as methods to develop neutralizing antibodies against IFN antagonists to treat viral infections.
    Type: Application
    Filed: June 5, 2014
    Publication date: May 21, 2015
    Inventors: Sergei V. Kotenko, Geoffrey L. Smith
  • Publication number: 20150133367
    Abstract: The present invention includes a novel class of highly specific protease inhibitors. In one embodiment, the inhibitors of the invention are ?-helical in structure. In another embodiment, the present invention represents the first demonstration of a highly specific cysteine protease inhibitor.
    Type: Application
    Filed: April 26, 2013
    Publication date: May 14, 2015
    Inventor: Doron C. Greenbaum
  • Publication number: 20150133368
    Abstract: Antiviral protease inhibitors, including macrocylic transition state inhibitors and peptidomimetics are disclosed, along with related antiviral compounds, and methods of using the same to treat or prevent viral infection and disease. The compounds possess broad-spectrum activity against viruses that belong to the picornavirus-like supercluster, which include important human and animal pathogens including noroviruses, sapoviruses, enteroviruses, poliovirus, foot-and-mouth disease virus, hepatitis A virus, human rhinovirus (cause of common cold), human coronavirus (another cause of common cold), transmissible gastroenteritis virus, murine hepatitis virus, feline infectious peritonitis virus, and severe acute respiratory syndrome coronavirus.
    Type: Application
    Filed: May 2, 2013
    Publication date: May 14, 2015
    Inventors: Kyeong-Ok Chang, Yunjeong Kim, William C. Groutas
  • Publication number: 20150118208
    Abstract: The present disclosure provides methods for generating enhanced affinity T cell receptors by agonist selection of hematopoietic progenitor cells expressing an antigen specific TCR? cultured with stromal cells expressing Delta-like-1 or Delta-like-4, compositions prepared from such methods, and uses of thereof.
    Type: Application
    Filed: May 2, 2013
    Publication date: April 30, 2015
    Inventors: Thomas M. Schmitt, Philip D. Greenberg
  • Patent number: 9017654
    Abstract: The present invention relates to a pharmaceutical preparation, comprising at least one Toll-like receptor ligand and at least one peptide. The invention also relates to the use of such a pharmaceutical preparation and to a vaccination method.
    Type: Grant
    Filed: October 6, 2005
    Date of Patent: April 28, 2015
    Assignee: Johannes-Gutenberg-Universitaet Mainz
    Inventors: Hansjoerg Schild, Tobias Warger, Markus Radsak, Gerd Rechtsteiner
  • Publication number: 20150111815
    Abstract: The present invention relates to a compound of formula (I): or pharmaceutically acceptable salt thereof, wherein the symbols are as defined in the specification; a pharmaceutical composition comprising the same; a method for treating or preventing a viral infection using the same.
    Type: Application
    Filed: October 24, 2014
    Publication date: April 23, 2015
    Inventors: Zhuang SU, Zhengyu LONG, Zhennian HUANG, Suizhou YANG
  • Publication number: 20150105316
    Abstract: This application describes compounds acting as, for example, ?-arrestin effectors and uses thereof, in, for example, the treatment of chronic and acute cardiovascular diseases.
    Type: Application
    Filed: December 22, 2014
    Publication date: April 16, 2015
    Inventors: Dennis Yamashita, Xiao-Tao Chen
  • Publication number: 20150104492
    Abstract: The present invention provides synthetic antibacterial peptides comprising a sequence at least 80% identical to a sequence shown in SEQ ID NO: 2 or the diastereomer thereof with a sequence shown in SEQ ID NO: 3 or pharmaceutical compositions thereof. Also provided are methods for reducing the severity of microbe-induced inflammation and for stimulating wound healing via the synthetic antibacterial peptides. Further provided is a device having a surface with a coating comprising the synthetic antibacterial peptides.
    Type: Application
    Filed: October 3, 2014
    Publication date: April 16, 2015
    Inventors: Alison McDermott, Marialuisa Mangoni
  • Publication number: 20150105315
    Abstract: The present invention relates to polypeptide fragments comprising an amino-terminal fragment of the PA subunit of a viral RNA-dependent RNA polymerase or variants thereof possessing endonuclease activity, wherein said PA subunit is from a virus belonging to the Orthomyxoviridae family. This invention also relates to (i) crystals of the polypeptide fragments which are suitable for structure determination of said polypeptide fragments using X-ray crystallography and (ii) computational methods using the structural coordinates of said polypeptide to screen for and design compounds that modulate, preferably inhibit the endonucleolytically active site within the polypeptide fragment. In addition, this invention relates to methods identifying compounds that bind to the PA polypeptide fragments possessing endonuclease activity and preferably inhibit said endonucleolytic activity, preferably in a high throughput setting.
    Type: Application
    Filed: October 21, 2014
    Publication date: April 16, 2015
    Applicants: EUROPEAN MOLECULAR BIOLOGY LABORATORY (EMBL), UNIVERSITY JOSEPH FOURIER FILIALE, Centre National de la Recherche Scientifique - Direction de la Politique Industrielle
    Inventors: Denis Bouvier, Thibaut Crepin, Rob Ruigrok, Alexander Dias, Stephen Cusack
  • Publication number: 20150104466
    Abstract: The present invention relates to methods and compositions for inhibiting the entry of viruses, such as herpesviruses into a host cell. A conserved viral integrin-binding gB disintegrin-like domain has been identified that engages integrins and facilitates viral internalization into the host cell. Therefore, methods and compositions, such as antiviral agents encompassing the conserved gB disintegrin-like domain and antibodies thereto are described. These active agents interfere with the interaction between virions and cellular integrins, thereby inhibiting viral infection of a host cell.
    Type: Application
    Filed: October 16, 2013
    Publication date: April 16, 2015
    Applicant: WISCONSIN ALUMNI RESEARCH FOUNDATION
    Inventors: Teresa Compton, Adam L. Feire
  • Patent number: 8999925
    Abstract: The present invention describes peptides which inhibit fusion of an arenavirus (e.g., Pichinde virus; PICV) with a host cell membrane. The arenavirus inhibiting (AVI) peptides described herein comprise a segment of the GP2 protein of an arenavirus. The AVI peptides are useful for inhibiting arenavirus-to-host cell membrane fusion and for treating arenavirus infections. In a particular embodiment, the arenavirus inhibiting peptide comprises a segment of PICV glycoprotein 2 (PICV GP2; SEQ ID NO: 1), Tamiami virus (TAMV) GP2 (SEQ ID NO: 14), or Lassa virus (LASV) GP2 (SEQ ID NO: 15). In particular, the segment is selected from a region of an arenavirus GP2 extending from the N-terminus into the first half of the FIR (i.e., from residues 1 through 105 of SEQ ID NO: 1, SEQ ID NO: 14, or SEQ ID NO: 15).
    Type: Grant
    Filed: March 14, 2013
    Date of Patent: April 7, 2015
    Assignee: The Administrators of the Tulane Educational Fund
    Inventors: Jennifer S. Spence, Robert F. Garry
  • Publication number: 20150087581
    Abstract: The present invention provides immunosuppression compounds to inhibit the programmed cell death 1 (PD1) signalling pathway. The present invention further provides peptide based compositions for treatment of cancer or treatment of infections via immunopotentiation caused by inhibition of immunosuppressive signaling induced by PD-1, PD-L1, or PD-L2 and therapies using them, immunopotentiative substrates included as the active ingredient. Further, the invention provides an application of the compositions containing the peptide moieties for preventive and/or therapeutic agents for cancer, cancer metastasis, immunodeficiency, an infectious disease or the like and an application of peptide moieties as a testing or diagnostic agent or a research agent for such a disease.
    Type: Application
    Filed: December 8, 2014
    Publication date: March 26, 2015
    Applicant: AURIGENE DISCOVERY TECHNOLOGIES LIMITED
    Inventors: Pottayil Govindan Nair Sasikumar, Muralidhara Ramachandra, Suresh Kumar Vadlamani, Koteswara Rao Vemula, Leena Khare Satyam, Krishnaprasad Subbarao, K. Rajeev Shrimali, Sreenivas Kandepu
  • Patent number: 8987195
    Abstract: The present invention relates to hepatitis C virus (HCV) NS3 protease inhibitors containing a spirocyclic moeity, uses of such compounds, and synthesis of such compounds.
    Type: Grant
    Filed: August 6, 2013
    Date of Patent: March 24, 2015
    Assignees: Merck Sharp & Dohme Corp., Merck Canada Inc.
    Inventors: Thomas Bara, Sathesh Bhat, Dipshikha Biswas, Linda Brockunier, Duane A. Burnett, Samuel Chackalamannil, Mariappan V. Chelliah, Austin Chen, Martin Clasby, Vince J. Colandrea, Zhuyan Guo, Yongxin Han, Charles Jayne, Hubert Josien, Karen Marcantonio, Shouwu Miao, Santhosh Neelamkavil, Patrick Pinto, Murali Rajagopalan, Unmesh Shah, Francisco Velazquez, Srikanth Venkatraman, Yan Xia
  • Publication number: 20150080289
    Abstract: Disclosed are amphiphilic peptides. Also disclosed are methods of treating proliferative disease, bacterial infection, viral infection and fungal infection, endotoxin neutralization and a method of removing biofilm. Also disclosed is the use of the amphiphilic peptides.
    Type: Application
    Filed: August 29, 2013
    Publication date: March 19, 2015
    Inventors: Yi-Yan Yang, Zhan Yuin Ong
  • Publication number: 20150080293
    Abstract: The present invention relates to chemical compounds, methods for their discovery, and their therapeutic and research use. In particular, the present invention provides antiviral and antimicrobial lectin compounds and methods of their use.
    Type: Application
    Filed: October 2, 2014
    Publication date: March 19, 2015
    Inventors: David Markovitz, Michael Swanson, Irwin Goldstein, Harry Winter
  • Publication number: 20150080292
    Abstract: This invention provides new cyclic lipopeptide antibiotic Locillomycin (Locillomycin-A, Locillomycin-B, Locillomycin-C) that display very strong antifungal, antibacterial, antivirus activities in a variety of contexts in vitro; methods of making and using the compounds, wherein Locillomycin-A, Locillomycin-B and Locillomycin-C are derived and purified from the culture of Bacillus subtilis Bs916.
    Type: Application
    Filed: February 26, 2014
    Publication date: March 19, 2015
    Inventor: Chuping Luo
  • Publication number: 20150065418
    Abstract: The present invention relates to compositions and methods for preventing, treating or delaying various cardiovascular diseases or disorders in mammals, particularly in humans. More particularly, the present invention provides for compositions and methods for preventing, treating or delaying various cardiovascular diseases or disorders using, inter alia, a neuregulin protein, or a functional fragment thereof, or a nucleic acid encoding a neuregulin protein, or a functional fragment thereof, or an agent that enhances production and/or function of said neuregulin.
    Type: Application
    Filed: May 6, 2014
    Publication date: March 5, 2015
    Applicant: Zensun (Shanghai) Science & Technology Limited
    Inventor: Mingdong ZHOU
  • Publication number: 20150056166
    Abstract: The present invention relates to flavone derivatives and to compositions containing one or more of these flavone derivatives. The present invention further relates to flavone derivatives or compositions for use in the treatment and/or prevention of a viral infection, and to a method of preventing or treating these infections.
    Type: Application
    Filed: March 22, 2013
    Publication date: February 26, 2015
    Inventors: Thomas Pietschmann, Sibylle Haid, Juliane Gentzsch, Christina Grethe, Elisabeth Davioud-Charvet, Don Antoine Lanfranchi, Mourad Elhabiri, Xavier Benlloch-Martin
  • Publication number: 20150056165
    Abstract: The present invention relates to novel cyclosporine analogues having antiviral activity against HCV and useful in the treatment of HCV infections. More particularly, the invention relates to novel cyclosporine analogue compounds, compositions containing such compounds and methods for using the same, as well as processes for making such compounds.
    Type: Application
    Filed: August 26, 2014
    Publication date: February 26, 2015
    Inventors: Yat Sun Or, Guoqiang Wang, Jiang Long, In Jong Kim
  • Patent number: 8962810
    Abstract: The present invention discloses a class of novel macro-heterocyclic compounds represented by the formula Ia or Ib, and their intermediates, preparation methods and the uses. The macro-heterocyclic compounds of the present invention have good inhibitory activities against hepatitis C virus (HCV), and can be used to treat HCV infection effectively by its excellent inhibition against HCV, low toxicity and side effects.
    Type: Grant
    Filed: June 14, 2012
    Date of Patent: February 24, 2015
    Assignee: AB Pharma Ltd.
    Inventor: Zheng-yun James Zhan
  • Publication number: 20150051139
    Abstract: The invention provides methods, and compositions for performing the methods, that reduce the diffusion or overall mobility of a virus on a surface, such as a biological surface using a purified mucin. The methods can reduce the infectivity of a virus for a cell on the surface. In particular embodiments, the mucin can be a non-human mucin, such as a procine gastric mucin.
    Type: Application
    Filed: February 6, 2013
    Publication date: February 19, 2015
    Applicant: Massachusetts Institute of Technology
    Inventors: Oliver Lieleg, Katharina Ribbeck
  • Publication number: 20150051138
    Abstract: Disclosed herein are Furin/PC inhibitors for inhibiting Furin and other Propprotein Convertases. Method of making the Furin/PC inhibitors, chemical and biological characterization of the Furin/PC inhibitors, and the use of the Furin/PC inhibitors to treat infectious diseases, cancers, and inflammatory/autoimmune disorders, are also disclosed.
    Type: Application
    Filed: March 14, 2013
    Publication date: February 19, 2015
    Applicant: Sanford-Burnham Medical Research Institute
    Inventors: Alex Strongin, Maurizio Pellecchia, Elisa Barile
  • Patent number: 8957018
    Abstract: Methods of using recombinant human CC10 (rhCC10), also known as recombinant human uteroglobin, to reduce virus titers in the tissues of patients, particularly influenza titers in lung tissues are provided. RhCC10 may be used as a therapeutic in the treatment, cure, or prevention of viral infection, particularly influenza infection. More particularly, methods, including broadly the critical dosage ranges of rhCC10, intravenous and intranasal route of administration, which may be administered to treat, cure or prevent influenza infection are provided. Further provided are compositions useful in the foregoing methods and in administering rhCC10 to humans.
    Type: Grant
    Filed: October 13, 2010
    Date of Patent: February 17, 2015
    Assignee: Therabron Therapeutics, Inc.
    Inventors: Aprile L Pilon, Pierre Borgeat, Louis Flamand
  • Publication number: 20150044188
    Abstract: Molecules secreted or derived from probiotic bacteria are provided for use in compositions and methods for the treatment and/or prevention of infection by pathogenic viruses. The isolated secreted molecules can also be used in nutritional or medical food products which provide probiotics to the gastrointestinal tract of a mammal.
    Type: Application
    Filed: August 12, 2014
    Publication date: February 12, 2015
    Inventor: Mansel Griffiths
  • Publication number: 20150037281
    Abstract: The present invention relates to novel Prothymosin Alpha (ProT?) variants that are capable of inducing cell-mediated immune responses. These variants lack a nuclear localization signal and the proliferative oncogenic activity previously attributed to ProT?. The variants of the invention are used in methods of treating, for example, viral infections, bacterial infections, fungal infections, cancer, ischemia and myeloproliferative blood disorders. Administration of a ProT? variant to a subject in a therapeutically effective amount treats the infection or disease.
    Type: Application
    Filed: March 1, 2013
    Publication date: February 5, 2015
    Applicant: Icahn School of Medicine at Mount Sinai
    Inventors: Arevik Mosoian, Avelino Teixeira
  • Publication number: 20150038408
    Abstract: The present invention provides polypeptides that recognize and are strong binders to Influenza A hemagglutinin and can be used, for example, to treat and/or limit development of an influenza infection. The present invention further provides isolated nucleic acids encoding the polypeptides of the invention, recombinant expression vectors comprising the nucleic acids encoding the polypeptides of the invention operatively linked to a suitable control sequence, and recombinant host cells comprising the recombinant expression vectors of the invention. The present invention also provides antibodies that selectively bind to the polypeptides of the invention, and pharmaceutical compositions comprising one or more polypeptides according to the invention and a pharmaceutically acceptable carrier.
    Type: Application
    Filed: March 12, 2013
    Publication date: February 5, 2015
    Inventors: David Baker, Timothy A. Whitehead, Sarel Fleishman
  • Patent number: 8940686
    Abstract: A novel cytokine, U83A, is described, as are variant forms of the cytokine, having a wide range of agonistic and antagonistic activity against chemokine receptors. Uses of the chemokine in treatment of a range of diseases, including cancers and HIV/AIDS, are described.
    Type: Grant
    Filed: May 25, 2006
    Date of Patent: January 27, 2015
    Assignee: London School of Hygiene and Tropical Medicine
    Inventors: Ursula Gompels, Julie Catusse, David Dewin
  • Patent number: 8940867
    Abstract: Methods for preparing viral neuraminidase inhibitors including antiviral peptides by specifically chemically modifying disulfide bonds in precursor molecules. A method of inhibiting viral neuraminidases by administering a viral neuraminidase inhibitor comprising an antiviral peptide prepared by the above methods and inhibiting the viral neuraminidase. Therapeutics for inhibiting viral neuraminidases, including effective amounts of viral neuraminidase inhibitors including antiviral peptides derived from selectively chemically modified disuifide bonds in precursor molecules, and present in a pharmaceutically acceptable carriers.
    Type: Grant
    Filed: July 17, 2007
    Date of Patent: January 27, 2015
    Assignee: Nuovo Biologics, LLC
    Inventors: Kent D. Miller, Billy S. Austin
  • Publication number: 20150023912
    Abstract: The present invention relates to a composition comprising at least two different albumin-based drug delivery systems, as well as to a pharmaceutical composition comprising said composition.
    Type: Application
    Filed: February 21, 2013
    Publication date: January 22, 2015
    Inventors: Felix Kratz, Andre Warnecke
  • Publication number: 20150011465
    Abstract: Novel peptoid oligomers are disclosed that have a formula represented by the following formula I: The peptoids demonstrate antimicrobial activity and may be prepared as pharmaceutical compositions and used for the prevention or treatment of a variety of conditions in mammals including humans where microbial invasion is involved. The present cyclic and linear peptoids are particularly valuable as their effect is rapid, broad in spectrum and mostly indifferent to resistance provoked by standard antibiotics.
    Type: Application
    Filed: September 9, 2014
    Publication date: January 8, 2015
    Inventors: Kent Kirshenbaum, Sung Bin Shin
  • Publication number: 20150004175
    Abstract: The compositions and methods described herein are useful for diminishing CTL exhaustion in a subject in need thereof, during an immune response to a viral infection or during an immune response to cancer, thereby leading to a greater CTL response against the viral infection or cancer. The invention relates to compositions and methods for the therapeutic intervention of signaling through EP2 and EP4, by inhibiting at least one of EP2, EP4, PGE2, or combinations thereof. The invention also relates to compositions and methods for the therapeutic intervention of signaling through EP2 and EP4, in combination with the therapeutic intervention of signaling through PD-1, by inhibiting at least one of EP2, EP4, PGE2, or combinations thereof, in combination with inhibiting at least one of PD-1, PD-L1, PD-L2, and combinations thereof.
    Type: Application
    Filed: December 13, 2012
    Publication date: January 1, 2015
    Inventors: Susan Kaech, Jonathan Chen
  • Publication number: 20150005228
    Abstract: Disclosed is the method of treating keratits in a subject thereof comprising administering into the subject an amphiphilic peptides of the present disclosure. Also disclosed are methods of removing biofilm from cornea.
    Type: Application
    Filed: July 1, 2014
    Publication date: January 1, 2015
    Inventors: Yi-Yan Yang, Zhan Yuin Ong
  • Publication number: 20150005227
    Abstract: Disclosed are peptide ligands for G-protein coupled receptors that are useful for treating disorders associated with G-protein coupled receptor activation.
    Type: Application
    Filed: September 7, 2014
    Publication date: January 1, 2015
    Inventors: YOSSI COHEN, RONEN SHEMESH, AMIR TOPORIK, ZURIT LEVINE, ASSAF WOOL, DVIR DAHARY, IRIS HECHT, GALIT ROTMAN, MICHAL AYALON-SOFFER
  • Patent number: 8916519
    Abstract: The present invention includes compositions and methods related to the structure and function of the cellular polyadenylation and specificity factor 30 (CPSF30) binding site on the surface of the influenza A non-structural protein 1 (NS1). Specifically, critical biochemical reagents, conditions for crystallization and NMR analysis, assays, and general processes are described for (i) discovering, designing, and optimizing small molecule inhibitors of influenza A (avian flu) viruses and (ii) creating attenuated influenza virus strains suitable for avian and human flu vaccine development.
    Type: Grant
    Filed: June 24, 2014
    Date of Patent: December 23, 2014
    Assignees: Rutgers, The State University of New Jersey, Board of Regents, The University of Texas System
    Inventors: Gaetano T. Montelione, Kalyan Das, Edward Arnold, Li-Chung Ma, Rong Xiao, Robert M. Krug, Karen Y. Twu, Rei-Lin Kuo
  • Publication number: 20140371137
    Abstract: The present invention relates to methods and compositions pertaining to conjugates comprising a nucleic acid oligomer conjugated to a glucosamine or a derivative thereof which are useful for inhibiting the transcription of target nucleic acids. The conjugates of the invention exhibit advantageous bioavailability and readily penetrate cell membranes which make them useful for inhibiting translation of target mRNA in vivo.
    Type: Application
    Filed: June 13, 2014
    Publication date: December 18, 2014
    Inventors: Virendra Pandey, Jean-Luc Decout, Indrajit Das, Jerome Desire
  • Publication number: 20140364358
    Abstract: A peptide is described, which consists of 7-17 adjacent amino acids and comprises the hexamer TXEXXE, wherein X, X and X can be any natural or non-natural amino acid, wherein the peptide has no TNF receptor binding activity and is cyclized, for the prevention and treatment of hyperpermeability of epithelial cells and endothelial cells.
    Type: Application
    Filed: March 7, 2014
    Publication date: December 11, 2014
    Applicant: Apeptico Forschung UND Entwicklung GMBH
    Inventors: Bernhard Fischer, Rudolf Lucas